Reverse Transcriptase Inhibitors for Alzheimer’s APP Variant Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Alzheimer's disease, such as antibody-based therapies targeting amyloid beta proteins, have not shown functional or cognitive improvement and are associated with significant side effects, while the role of amyloid precursor protein (APP) gene variants in AD pathogenesis remains unclear.
Innovation Solution
Inhibiting the generation of non-classical variants of the APP gene in individuals with Alzheimer's disease by administering reverse transcriptase inhibitors, which can include nucleoside or non-nucleoside reverse transcriptase inhibitors, along with other therapeutic agents like cholinesterase inhibitors or anti-amyloid beta antibodies, to reduce amyloid beta protein accumulation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If antibody-based therapies are used to eliminate amyloid beta proteins, then amyloid beta accumulation is reduced, but functional or cognitive improvement is not achieved and significant side effects occur
Solution Approach 1:
The patent extracts and inhibits the generation of non-classical APP gene variants using reverse transcriptase inhibitors, separating this specific pathological mechanism from the overall APP processing pathway. This targeted approach addresses the root cause of amyloid beta accumulation without the side effects of broad antibody-based therapies.
Solution Approach 2:
The patent applies preliminary action by inhibiting the generation of non-classical APP variants before they can be processed into amyloid beta proteins. Reverse transcriptase inhibitors prevent the formation of these problematic gene variants at an early stage, preventing downstream amyloid accumulation rather than attempting to clear it afterward.
2Quantity of substance
If antibody-based therapies are used to eliminate amyloid beta proteins, then amyloid beta accumulation is reduced, but significant side effects occur
Solution Approach 1:
The patent converts the harmful effect of reverse transcriptase inhibitors (which can cause mitochondrial toxicity) into a beneficial outcome by demonstrating that these same inhibitors effectively block the generation of non-classical APP variants. The treatment leverages the inhibitors' ability to block reverse transcription while using lower doses to minimize mitochondrial side effects.
Solution Approach 2:
The patent introduces reverse transcriptase inhibitors as an intermediary mechanism between the APP gene and amyloid beta protein production. Rather than directly targeting amyloid beta with antibodies, the inhibitors act upstream to prevent the formation of non-classical APP variants that lead to amyloid accumulation, providing a more indirect but safer therapeutic approach.
3Quantity of substance
If reverse transcriptase inhibitors are administered to inhibit non-classical APP variant generation, then amyloid beta accumulation is reduced, but the mechanism of action is not well understood
Solution Approach 1:
The patent establishes feedback loops to monitor the effectiveness of reverse transcriptase inhibitors in reducing non-classical APP variant generation and amyloid beta accumulation. By measuring APP variant levels and amyloid accumulation in response to treatment, the mechanism can be better understood and optimized through iterative adjustment of dosing and inhibitor selection.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Reduces amyloid beta protein accumulation and plaque formation, potentially leading to improved cognitive function and reduced side effects compared to existing treatments.
Implementation Method 1
administering to the individual a reverse transcriptase inhibitor or salt thereof to inhibit generation of one or more non-classical variant(s) of an amyloid precursor protein (APP) gene
Data Source
AI summary
Described herein are methods for inhibiting generation of one or more non-classical variant(s) of amyloid precursor protein (APP) gene. Provided herein are methods for diagnosing an individual having or suspected of having Alzheimer's disease following identification of an expression profile or an activity profile of the one or more non-classical variant(s) and treating the individual using a reverse transcriptase inhibitor or salt thereof.